A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumor
In brief
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Key facts
- Study ID
- NCT04158336
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- People needed
- 274
- Starts
- 2019-11-01
- Expected to finish
- 2025-05-06
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Site 0102 — Tucson, Arizona, United States
- Site 0167 — Newport Beach, California, United States
- Site 0171 — Chicago, Illinois, United States
- Site 0101 — Detroit, Michigan, United States
- Site 0173 — New York, New York, United States
- Site 0179 — Pittsburgh, Pennsylvania, United States
- Site 0103 — Houston, Texas, United States
- Site 0100 — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.